newsfilter
← Latest News
ACCESS Newswire·

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research clinical trial by end of March 2025 -- The Company recently entered into a Clinical Trial